Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo.
about
Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's diseaseA reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.α7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimumCreating an 7 Nicotinic Acetylcholine Recognition Domain from the Acetylcholine-binding Protein: CRYSTALLOGRAPHIC AND LIGAND SELECTIVITY ANALYSESMultifunctional receptor-directed drugs for disorders of the central nervous systemEndogenous opioids suppress activation of nociceptors by sub-nanomolar nicotineStable expression and functional characterization of a human nicotinic acetylcholine receptor with α6β2 properties: discovery of selective antagonistsDifferential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in ratsNicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disordersEffects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in ratsCognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptorMuscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophreniaBeyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task.[11C]CHIBA-1001 as a novel PET ligand for alpha7 nicotinic receptors in the brain: a PET study in conscious monkeys.First-principles calculation of pKa for cocaine, nicotine, neurotransmitters, and anilines in aqueous solution.The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control.Intrathecal injection of an alpha seven nicotinic acetylcholine receptor agonist attenuates gp120-induced mechanical allodynia and spinal pro-inflammatory cytokine profiles in rats.Cardiopulmonary arrest and resuscitation disrupts cholinergic anti-inflammatory processes: a role for cholinergic α7 nicotinic receptors.The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeysBrain imaging of nicotinic receptors in Alzheimer's disease.α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease.SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.alpha7 nicotinic acetylcholine receptor agonist properties of tilorone and related tricyclic analogues.Nicotinic acetylcholine receptors as targets for antidepressants.Modeling binding modes of alpha7 nicotinic acetylcholine receptor with ligands: the roles of Gln117 and other residues of the receptor in agonist binding.A type-II positive allosteric modulator of α7 nAChRs reduces brain injury and improves neurological function after focal cerebral ischemia in rats.Alzheimer's disease and age-related memory decline (preclinical)Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.Modeling multiple species of nicotine and deschloroepibatidine interacting with alpha4beta2 nicotinic acetylcholine receptor: from microscopic binding to phenomenological binding affinitySynthesis and positron emission tomography studies of C-11-labeled isotopomers and metabolites of GTS-21, a partial alpha7 nicotinic cholinergic agonist drug.Modulation of aggressive behavior in mice by nicotinic receptor subtypes.Effects of nicotine and mecamylamine on cognition in rhesus monkeys.Critical Molecular Determinants of α7 Nicotinic Acetylcholine Receptor Allosteric Activation: SEPARATION OF DIRECT ALLOSTERIC ACTIVATION AND POSITIVE ALLOSTERIC MODULATION.
P2860
Q21131066-98813257-BEB0-45ED-95DC-F9DFA3663ACCQ24650678-E9385FCC-8D5F-4889-BE2A-BB5DB2073A49Q26852967-86EEC54D-84BE-451C-8C42-B7E51B409AF3Q27675116-ED6FB332-2D19-4079-AFE0-A0E8B07AE170Q28305096-07F1C600-B6E3-4F87-B434-1651DF97A493Q28363775-2E6626CE-51E4-4337-965C-6AA8C9B3FD14Q28388268-7BC3F3E5-A64E-4D96-8D49-DDFCE1B0AF93Q28477881-5BD2DDF6-DE00-4ED1-8F75-1A886E160BDCQ30372351-51CA5989-032E-4154-BE27-84843ABF0E04Q30391389-632ECC7A-B78B-49AC-A265-B2D5D295FD0CQ30396291-CAECC476-E980-4414-A09C-9BCAF1C12725Q30407039-C5A70F6B-0649-4FEA-8BEE-4D4F311E3B12Q30453198-94B53456-335E-462D-96D9-D94C3A0249A0Q30459624-29965325-BCA7-40B1-848E-1E6223C82930Q30473410-6FC7EE78-B530-4603-9731-BAA8BF4231C1Q30493072-55FA6C38-DDAE-4365-BDE8-A26A425C45F1Q30501338-6BB56DFC-AFA9-4129-99CC-C9BC9F665FACQ33370286-44D1DE82-B6FA-486B-8A81-DC5BC3E0EABCQ33900007-D880765D-7FCB-416F-9CB8-F2D57FC23E14Q33956671-96F902A2-C72E-449B-B6D6-4E06EDB5BFC3Q33988241-859A9D6C-45D3-48E6-A66C-5DFD14C85EE9Q34168098-4AB9A4FE-070A-4139-81E5-195DB0436AF4Q34186299-E5B215B0-5178-4CCB-9466-581CD5195AF8Q34496928-886CB256-046E-498D-B3D0-981781421EBFQ34501147-9C7A2901-85D8-43E8-BE8D-F509BB1EF2D1Q34561031-757F010D-F3FD-4464-90A0-38FFA4F23748Q34586463-4DC58687-2736-42B2-B444-D6EE38186375Q34761238-BFD74C24-85B7-4CD1-8887-3234195314A2Q34796673-E73D7707-6E29-48A8-841F-344DEF209AAEQ34952107-BC81F60B-47D9-4225-8AF8-DD1C5B6D6963Q35041190-97FBB62A-E255-477E-9830-49134F81AFBFQ35044540-C081CBA8-51F0-4605-9158-AA4EF30CB0CFQ35048154-34AF8E4A-A490-4A59-A6B4-B924F75114C2Q35111465-224F9F3D-5F41-4927-BCAF-99DF1F248819Q35182164-461307EB-6907-47F5-8F0D-14B7F6673A52Q35238525-F646AF7B-4222-44E9-8E55-B42906E0059CQ35240381-857DCFFB-CC37-4AC3-A06C-2D3C3194667FQ36144924-77F6B386-44AD-4EE3-9C7D-B1552ADDB14FQ36238293-03D70AF3-9DD4-495B-8A4F-2A2E2F6CD5F7Q36650296-96FC19A1-C338-4EDC-86EB-580FEF873285
P2860
Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo.
description
1997 nî lūn-bûn
@nan
1997 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Functional characterization of ...... d GTS-21 in vitro and in vivo.
@ast
Functional characterization of ...... d GTS-21 in vitro and in vivo.
@en
Functional characterization of ...... d GTS-21 in vitro and in vivo.
@nl
type
label
Functional characterization of ...... d GTS-21 in vitro and in vivo.
@ast
Functional characterization of ...... d GTS-21 in vitro and in vivo.
@en
Functional characterization of ...... d GTS-21 in vitro and in vivo.
@nl
prefLabel
Functional characterization of ...... d GTS-21 in vitro and in vivo.
@ast
Functional characterization of ...... d GTS-21 in vitro and in vivo.
@en
Functional characterization of ...... d GTS-21 in vitro and in vivo.
@nl
P2093
P1476
Functional characterization of ...... d GTS-21 in vitro and in vivo.
@en
P2093
Anderson DJ
Arneric SP
Buccafusco JJ
Buckley MJ
Campbell JE
Donnelly-Roberts D
Elliott RL
P304
P356
10.1016/S0091-3057(96)00354-1
P407
P577
1997-05-01T00:00:00Z